Targeted delivery of antibody-based therapeutic and imaging agents to CNS tumors: crossing the blood-brain barrier divide.

Details

Serval ID
serval:BIB_1121EC274D7E
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Title
Targeted delivery of antibody-based therapeutic and imaging agents to CNS tumors: crossing the blood-brain barrier divide.
Journal
Expert Opinion on Drug Delivery
Author(s)
Chacko A.M., Li C., Pryma D.A., Brem S., Coukos G., Muzykantov V.
ISSN
1744-7593 (Electronic)
ISSN-L
1742-5247
Publication state
Published
Issued date
2013
Volume
10
Number
7
Pages
907-926
Language
english
Notes
Publication types: Journal Article ; Research Support, N.I.H., Extramural ; ReviewPublication Status: ppublish
Abstract
INTRODUCTION: Brain tumors are inherently difficult to treat in large part due to the cellular blood-brain barriers (BBBs) that limit the delivery of therapeutics to the tumor tissue from the systemic circulation. Virtually no large molecules, including antibody-based proteins, can penetrate the BBB. With antibodies fast becoming attractive ligands for highly specific molecular targeting to tumor antigens, a variety of methods are being investigated to enhance the access of these agents to intracranial tumors for imaging or therapeutic applications.
AREAS COVERED: This review describes the characteristics of the BBB and the vasculature in brain tumors, described as the blood-brain tumor barrier (BBTB). Antibodies targeted to molecular markers of central nervous system (CNS) tumors will be highlighted, and current strategies for enhancing the delivery of antibodies across these cellular barriers into the brain parenchyma to the tumor will be discussed. Noninvasive imaging approaches to assess BBB/BBTB permeability and/or antibody targeting will be presented as a means of guiding the optimal delivery of targeted agents to brain tumors.
EXPERT OPINION: Preclinical and clinical studies highlight the potential of several approaches in increasing brain tumor delivery across the BBB divide. However, each carries its own risks and challenges. There is tremendous potential in using neuroimaging strategies to assist in understanding and defining the challenges to translating and optimizing molecularly targeted antibody delivery to CNS tumors to improve clinical outcomes.
Keywords
Antibodies, Monoclonal, Antibodies, Neoplasm/diagnostic use, Antibodies, Neoplasm/therapeutic use, Biological Transport, Blood-Brain Barrier/drug effects, Brain/blood supply, Brain Neoplasms/blood supply, Brain Neoplasms/therapy, Capillary Permeability, Drug Delivery Systems, Humans, Immunotoxins/therapeutic use, Neuroimaging/methods, Pharmaceutical Preparations/administration & dosage
Pubmed
Web of science
Create date
14/10/2014 11:43
Last modification date
20/08/2019 12:38
Usage data